LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.

Photo by nci from unsplash

9515Background: PD-1/L1 inhibitors have transformed MM treatment, however many patients (pts) remain refractory. Subsequent treatment options including ipi offer modest benefit (~13% respond) (Long... Click to show full abstract

9515Background: PD-1/L1 inhibitors have transformed MM treatment, however many patients (pts) remain refractory. Subsequent treatment options including ipi offer modest benefit (~13% respond) (Long...

Keywords: study evaluate; ipi; safety efficacy; evaluate safety; efficacy intratumoral; phase study

Journal Title: Journal of Clinical Oncology
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.